Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

DexCom Inc. operates as a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes. The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals.
Website: dexcom.com



Growth: Good revenue growth rate 24.1%, there is acceleration compared to average historical growth rates 23.5%. The revenue growth dynamics is stable Site traffic for the last 3 months showed a change of +18.9%

Profitability: LTM EBITDA margin is positive, +20.9%. In the last quarter the company beat the estimated EPS, +13.3%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 103.0% higher than minimum and 15.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.7x by EV / Sales multiple , the company can be 73.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $28.8 mln (-0.054% of cap.)

Key Financials (Download financials)

Ticker: DXCM
Share price, USD:  (+0.1%)138.01
year average price 116.70  


year start price 123.58 2023-04-27

min close price 75.49 2023-10-12

max close price 140.45 2024-04-09

current price 138.01 2024-04-25
Common stocks: 392 503 987

Dividend Yield:  0.0%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 67.6x
EV / EBITDA annualized: 130.5x
Last revenue growth (y/y):  24.1%
Last growth of EBITDA (y/y):  110.2%
Historical revenue growth:  23.5%
Historical growth of EBITDA:  42.1%
EV / Sales: 14.2x
Margin (EBITDA LTM / Revenue): 20.9%
Fundamental value created in LTM:
Market Cap ($m): 54 169
Net Debt ($m): -364
EV (Enterprise Value): 53 805
Price to Book: 26.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-24Zacks Investment Research

Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?

2024-04-22Zacks Investment Research

Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

2024-04-18Zacks Investment Research

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

2024-04-15Zacks Investment Research

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

2024-04-15Zacks Investment Research

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

2024-04-11Schwab Network

SLB, DXCM, CRH: The Economy is Relatively Healthy

2024-04-11Seeking Alpha

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

2024-04-08Zacks Investment Research

Why the Market Dipped But DexCom (DXCM) Gained Today

2024-04-04Zacks Investment Research

DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know

2024-04-02Zacks Investment Research

DexCom (DXCM) Falls More Steeply Than Broader Market: What Investors Need to Know
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-10-26 2023-07-27 2023-04-27 2023-02-09 2022-10-27
acceptedDate 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 035M 975M 871M 742M 815M 770M
costOfRevenue 378M 352M 325M 279M 274M 275M
grossProfit 657M 623M 546M 463M 541M 494M
grossProfitRatio 0.635 0.639 0.627 0.624 0.664 0.642
researchAndDevelopmentExpenses 136M 131M 119M 119M 116M 110M
generalAndAdministrativeExpenses 128M 0 0 0 0 0
sellingAndMarketingExpenses 181M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 309M 285M 297M 295M 298M 235M
otherExpenses -500 000 34M 0 2M 2M 2M
operatingExpenses 440M 418M 418M 415M 416M 347M
costAndExpenses 818M 770M 743M 694M 690M 622M
interestIncome 34M 42M 37M 22M 13M 3M
interestExpense 5M 5M 6M 5M 5M 5M
depreciationAndAmortization 53M 2M 2M 42M 14M 43M
ebitda 304M 207M 167M 111M 140M 190M
ebitdaratio 0.293 0.213 0.192 0.149 0.171 0.247
operatingIncome 217M 206M 128M 69M 125M 148M
operatingIncomeRatio 0.210 0.211 0.147 0.093 0.154 0.192
totalOtherIncomeExpensesNet 400 000 35M 31M -5M 8M -1M
incomeBeforeTax 246M 240M 159M 65M 133M 146M
incomeBeforeTaxRatio 0.238 0.247 0.183 0.087 0.163 0.190
incomeTaxExpense -10M 120M 43M 16M 41M 45M
netIncome 256M 121M 116M 49M 92M 101M
netIncomeRatio 0.248 0.124 0.133 0.066 0.113 0.131
eps 0.670 0.310 0.300 0.130 0.240 0.260
epsdiluted 0.620 0.290 0.280 0.120 0.220 0.240
weightedAverageShsOut 384M 387M 387M 387M 386M 390M
weightedAverageShsOutDil 416M 427M 432M 419M 426M 426M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-10-26 2023-07-27 2023-04-27 2023-02-09 2022-10-27
acceptedDate 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 566M 644M 1 195M 623M 642M 698M
shortTermInvestments 2 158M 2 597M 2 441M 1 944M 1 814M 1 674M
cashAndShortTermInvestments 2 724M 3 240M 3 636M 2 567M 2 456M 2 372M
netReceivables 988M 786M 751M 653M 713M 597M
inventory 560M 499M 421M 366M 307M 311M
otherCurrentAssets 49M 174M 195M 43M 193M 119M
totalCurrentAssets 4 426M 4 698M 5 003M 3 767M 3 669M 3 399M
propertyPlantEquipmentNet 1 185M 1 152M 1 154M 1 154M 1 136M 1 076M
goodwill 25M 25M 26M 26M 26M 25M
intangibleAssets 135M 145M 154M 164M 173M 24M
goodwillAndIntangibleAssets 160M 170M 180M 189M 199M 49M
longTermInvestments 39M 39M 0 0 0 0
taxAssets 419M 501M 417M 349M 341M 342M
otherNonCurrentAssets 37M 36M 67M 57M 47M 34M
totalNonCurrentAssets 1 839M 1 898M 1 818M 1 749M 1 723M 1 501M
otherAssets 0 0 0 0 0 0
totalAssets 6 265M 6 596M 6 821M 5 516M 5 392M 4 899M
accountPayables 276M 1 373M 1 157M 266M 902M 198M
shortTermDebt 21M 145M 796M 795M 793M 21M
taxPayables 50M 219M 60M 52M 45M 34M
deferredRevenue 18M 9M 9M 10M 10M 3M
otherCurrentLiabilities 1 240M 151M 109M 794M 134M 679M
totalCurrentLiabilities 1 556M 1 679M 2 070M 1 865M 1 839M 901M
longTermDebt 2 573M 2 516M 2 518M 1 347M 1 292M 2 111M
deferredRevenueNonCurrent 7M 21M 21M 21M 19M 24M
deferredTaxLiabilitiesNonCurrent 54M 5M 5M 5M 5M 5M
otherNonCurrentLiabilities 5M 108M 107M 45M 104M 1 953M
totalNonCurrentLiabilities 2 640M 2 650M 2 651M 1 418M 1 421M 2 174M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 160M 104M 109M 171M 115M 163M
totalLiabilities 4 196M 4 328M 4 720M 3 283M 3 260M 3 075M
preferredStock 0 0 0 0 0 0
commonStock 400 000 400 000 400 000 400 000 400 000 400 000
retainedEarnings 1 021M 765M 644M 529M 480M 388M
accumulatedOtherComprehensiveIncomeLoss -17M -36M -29M -7M -12M -41M
othertotalStockholdersEquity 1 064M 1 538M 1 485M 1 711M 1 663M 1 477M
totalStockholdersEquity 2 069M 2 268M 2 100M 2 233M 2 132M 1 825M
totalEquity 2 069M 2 268M 2 100M 2 233M 2 132M 1 825M
totalLiabilitiesAndStockholdersEquity 6 265M 6 596M 6 821M 5 516M 5 392M 4 899M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 6 265M 6 596M 6 821M 5 516M 5 392M 4 899M
totalInvestments 2 196M 2 597M 2 441M 1 944M 1 814M 1 674M
totalDebt 2 594M 2 661M 3 313M 2 143M 2 085M 2 132M
netDebt 2 028M 2 017M 2 118M 1 520M 1 443M 1 434M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-10-26 2023-07-27 2023-04-27 2023-02-09 2022-10-27
acceptedDate 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 256M 121M 116M 49M 92M 101M
depreciationAndAmortization 53M 48M 44M 42M 36M 39M
deferredIncomeTax 82M -85M -42M -9M 32M -34M
stockBasedCompensation 37M 39M 40M 35M 34M 31M
changeInWorkingCapital -258M 163M 47M 52M -65M 138M
accountsReceivables -187M -36M -114M 77M -148M -5M
inventory -59M -79M -55M -60M 6M 27M
accountsPayables -30M 220M 190M 87M 124M 75M
otherWorkingCapital 18M 58M 26M -52M -46M 41M
otherNonCashItems -36M -17M -14M -12M 3M 17M
netCashProvidedByOperatingActivities 134M 269M 190M 155M 133M 293M
investmentsInPropertyPlantAndEquipment -53M -50M -59M -75M -64M -108M
acquisitionsNet 0 0 0 0 0 -700 000
purchasesOfInvestments -253M -798M -1 340M -810M -869M -254M
salesMaturitiesOfInvestments 719M 671M 859M 698M 740M 602M
otherInvestingActivites 900 000 -3M -16M 0 -2M -10M
netCashUsedForInvestingActivites 415M -180M -556M -187M -194M 229M
debtRepayment -137M -651M 0 0 0 0
commonStockIssued 0 14M 0 12M 0 12M
commonStockRepurchased -500M 0 0 0 -558M 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 5M -1M 940M -1M 557M -565M
netCashUsedProvidedByFinancingActivities -632M -637M 940M 11M -1 000 000 -553M
effectOfForexChangesOnCash 6M -4M -2M 1M 7M -7M
netChangeInCash -77M -551M 572M -19M -56M -37M
cashAtEndOfPeriod 568M 645M 1 196M 624M 643M 699M
cashAtBeginningOfPeriod 645M 1 196M 624M 643M 699M 736M
operatingCashFlow 134M 269M 190M 155M 133M 293M
capitalExpenditure -53M -50M -59M -75M -64M -108M
freeCashFlow 81M 219M 131M 81M 69M 185M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-08 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-09 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-03 13:00 ET
Dexcom Publishes Annual Sustainability Report
2024-04-02 12:30 ET
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
2024-03-05 21:26 ET
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
2024-03-05 08:00 ET
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
2024-02-27 21:05 ET
Dexcom Announces Upcoming Conference Presentation
2024-02-08 21:02 ET
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
2024-02-06 07:00 ET
Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People
2024-01-23 13:30 ET
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
2024-01-19 07:00 ET
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
2024-01-15 08:30 ET
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
2024-01-08 13:00 ET
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
2023-12-19 13:30 ET
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 13:00 ET
Synchron Appoints Andy Rasdal to Board of Directors
2023-12-06 13:40 ET
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
2023-11-21 13:30 ET
Dexcom Announces Upcoming Conference Presentation
2023-11-14 05:01 ET
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day
2023-11-08 09:00 ET
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
2023-10-26 20:03 ET
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program
2023-10-05 12:30 ET
Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada
2023-10-02 06:00 ET
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
2023-09-29 12:30 ET
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
2023-09-21 12:30 ET
Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition
2023-09-19 10:00 ET
Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program
2023-09-12 08:00 ET
Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France
2023-09-01 08:00 ET
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany
2023-08-30 12:30 ET
Dexcom Announces Upcoming Conference Presentations
2023-08-28 12:30 ET
Dexcom Appoints Rimma Driscoll to Board of Directors
2023-08-15 12:30 ET
Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year
2023-07-27 20:03 ET
Dexcom Reports Second Quarter 2023 Financial Results
2023-07-06 12:30 ET
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
2023-07-04 12:30 ET
Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians
2023-06-24 00:15 ET
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
2023-06-24 00:00 ET
Dexcom Updates Long-Range Financial Targets
2023-06-21 08:00 ET
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System
2023-06-12 08:00 ET
New Study Shows That 84% of People With Diabetes Struggle With Mental Health¹
2023-06-08 12:30 ET
Dexcom to Host Investor Day on June 23, 2023
2023-06-01 12:30 ET
Dexcom Announces Upcoming Conference Presentation
2023-05-10 22:30 ET
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
2023-05-03 11:00 ET
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
2023-05-03 08:00 ET
Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests
2023-05-02 11:00 ET
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
2023-04-27 20:03 ET
Dexcom Reports First Quarter 2023 Financial Results
2023-04-27 10:00 ET
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
2023-04-17 12:00 ET
Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin
2023-04-06 09:30 ET
Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
2023-04-05 13:00 ET
Dexcom Publishes Annual Sustainability Report
2023-03-21 10:00 ET
Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors
2023-03-13 11:30 ET
DexCom Comments on SVB Relationship
2023-02-23 14:00 ET
Dexcom Announces Upcoming Conference Presentations
2023-02-22 05:00 ET
Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally
2023-02-13 13:30 ET
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
2023-02-09 21:03 ET
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2023-02-07 14:25 ET
Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System
2023-02-02 12:00 ET
Mednow Launches New Virtual Diabetes Management Program in Partnership With Dexcom
2023-01-24 14:00 ET
Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
2023-01-17 11:00 ET
Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
2023-01-09 13:00 ET
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
2023-01-09 13:00 ET
Dexcom Appoints Teri Lawver as Chief Commercial Officer
2023-01-03 14:00 ET
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 13:00 ET
Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience
2022-12-08 13:45 ET
Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
2022-11-30 16:25 ET
Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers
2022-11-22 14:00 ET
Dexcom Announces Upcoming Conference Presentation
2022-11-14 09:00 ET
Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches
2022-11-01 13:00 ET
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care
2022-10-27 20:03 ET
Dexcom Reports Third Quarter 2022 Financial Results
2022-10-24 12:00 ET
Dexcom, Adam Schefter Announce Dexcom U, the First NIL Program for College Athletes With Diabetes
2022-10-04 07:00 ET
Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System
2022-09-29 13:00 ET
Dexcom Schedules Third Quarter 2022 Earnings Release and Conference Call for October 27, 2022 at 4:30 p.m. Eastern Time.
2022-09-01 20:15 ET
Dexcom Announces Upcoming Conference Presentations
2022-08-31 21:00 ET
DexCom Promotes Jake Leach to Chief Operating Officer
2022-08-03 20:15 ET
Dexcom Announces Upcoming Conference Presentation
2022-08-01 23:00 ET
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
2022-07-28 20:03 ET
Dexcom Reports Second Quarter 2022 Financial Results
2022-07-27 12:45 ET
Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish
2022-07-19 10:00 ET
Dexcom Canada Achieves Great Place to Work® Certification
2022-06-30 20:04 ET
Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.
2022-06-13 08:00 ET
Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!
2022-06-02 12:30 ET
Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association
2022-06-01 10:00 ET
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
2022-05-31 12:30 ET
Dexcom Issues Statement on Recent Market Speculation
2022-05-23 12:00 ET
Dexcom Announces Upcoming Conference Presentation
2022-05-10 12:00 ET
Dexcom Announces Upcoming Conference Presentations
2022-04-28 21:27 ET
Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time
2022-04-28 20:03 ET
Dexcom Reports First Quarter 2022 Financial Results
2022-04-26 06:00 ET
DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes
2022-04-07 12:45 ET
Dexcom Publishes Annual Sustainability Report
2022-04-01 07:29 ET
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
2022-03-31 20:15 ET
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
2022-03-25 13:00 ET
Dexcom Announces Four-for-One Forward Stock Split
2022-03-14 07:30 ET
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
2022-03-07 11:00 ET
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
2022-03-01 21:05 ET
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System
2022-02-14 13:45 ET
Dexcom Announces Upcoming Virtual Conference Presentations
2022-02-10 21:03 ET
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2022-02-03 22:19 ET
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
2022-01-24 13:45 ET
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.
2022-01-10 12:45 ET
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial
2022-01-04 13:45 ET
Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-11-29 13:45 ET
Dexcom Announces Upcoming Conference Presentation
2021-11-01 12:45 ET
Dexcom, Nick Jonas, Patti LaBelle and The Global Movement for Time in Range Invite the World to #SeeDiabetes This November
2021-10-28 20:02 ET
Dexcom Reports Third Quarter 2021 Financial Results
2021-10-13 08:00 ET
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
2021-10-05 12:45 ET
Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time
2021-09-29 10:00 ET
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes
2021-09-13 17:00 ET
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
2021-09-02 12:45 ET
Dexcom Announces Upcoming Virtual Conference Presentations
2021-07-29 20:02 ET
Dexcom Reports Second Quarter 2021 Financial Results
2021-07-15 20:51 ET
FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
2021-07-07 12:45 ET
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
2021-06-25 12:45 ET
Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association
2021-06-24 14:00 ET
DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
2021-06-22 13:14 ET
Endurance Athlete Sébastien Sasseville to Ride Across Canada in Support of JDRF’s Access For All Campaign
2021-06-11 17:28 ET
British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy
2021-06-03 15:11 ET
Dexcom Looks to the Future of Continuous Glucose Monitoring
2021-05-27 12:45 ET
Dexcom Announces Upcoming Conference Presentation
2021-04-29 20:02 ET
Dexcom Reports First Quarter 2021 Financial Results
2021-04-07 07:00 ET
Dexcom Starts Direct Distribution in the Netherlands
2021-04-01 20:15 ET
Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time
2021-03-23 12:30 ET
Dexcom Promotes Jereme Sylvain to Chief Financial Officer
2021-02-17 13:45 ET
Dexcom Announces Upcoming Virtual Conference Presentations
2021-02-11 21:10 ET
Dexcom Launches Inaugural Venture Capital Fund
2021-02-11 21:02 ET
Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results
2021-02-02 15:00 ET
Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes
2021-01-19 13:30 ET
Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time
2021-01-11 12:30 ET
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
2021-01-05 13:30 ET
Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-11-12 13:45 ET
Dexcom Announces Upcoming Virtual Conference Presentations
2020-11-03 13:30 ET
Dexcom to Host Investor Day on December 9, 2020
2020-10-27 20:03 ET
Dexcom Reports Third Quarter 2020 Financial Results
2020-10-26 20:42 ET
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue
2020-10-13 12:30 ET
Dexcom Appoints Kyle Malady to Board of Directors
2020-10-01 12:30 ET
Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.
2020-09-24 12:30 ET
Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research
2020-09-22 12:30 ET
Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States
2020-09-16 12:30 ET
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
2020-09-04 12:45 ET
Dexcom Announces Upcoming Virtual Conference Presentations
2020-08-12 12:30 ET
 Dexcom Appoints Karen Dahut to Board of Directors
2020-08-10 20:05 ET
Dexcom Announces Upcoming Conference Presentation
2020-07-28 20:03 ET
Dexcom Reports Second Quarter 2020 Financial Results
2020-06-30 12:45 ET
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
2020-06-04 13:00 ET
Dexcom Announces Upcoming Conference Presentation
2020-05-12 11:00 ET
DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes
2020-05-11 11:00 ET
DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes
2020-05-08 21:52 ET
DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020
2020-04-28 20:03 ET
Dexcom Reports First Quarter 2020 Financial Results
2020-04-27 12:00 ET
Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic
2020-04-02 12:30 ET
Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time
2020-02-24 21:15 ET
Dexcom to Present at Cowen 40th Annual Healthcare Conference
2020-02-19 12:00 ET
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
2020-02-13 21:01 ET
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
2020-01-21 14:00 ET
Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time
2020-01-06 13:45 ET
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
2019-11-26 14:00 ET
Dexcom Announces Upcoming Conference Presentation
2019-11-08 14:00 ET
Dexcom Announces Upcoming Conference Presentation
2019-11-06 21:03 ET
Dexcom Reports Third Quarter 2019 Financial Results
2019-10-09 20:47 ET
Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time
2019-10-08 12:30 ET
Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM
2019-09-17 20:05 ET
Dexcom Promotes Quentin Blackford to Chief Operating Officer
2019-09-17 12:30 ET
Dexcom Appoints Bridgette Heller to Board of Directors
2019-07-31 20:03 ET
Dexcom Reports Second Quarter 2019 Financial Results

SEC forms

Show financial reports only

SEC form 8
2024-04-25 16:05 ET
DexCom published news for 2024 q1
SEC form 8
2024-04-25 16:05 ET
DexCom reported for 2024 q1
SEC form 8
2024-02-08 00:00 ET
DexCom reported for 2023 q4
SEC form 10
2024-02-08 00:00 ET
DexCom reported for 2023 q4
SEC form 8
2024-02-08 00:00 ET
DexCom published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
DexCom published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
DexCom published news for 2023 q4
SEC form 10
2023-10-26 17:14 ET
DexCom published news for 2023 q3
SEC form 8
2023-10-26 16:04 ET
DexCom reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
DexCom published news for 2023 q3
SEC form 10
2023-07-27 17:08 ET
DexCom reported for 2023 q2
SEC form 6
2023-07-27 16:05 ET
DexCom published news for 2023 q2
SEC form 8
2023-07-27 00:00 ET
DexCom published news for 2023 q2
SEC form 10
2023-07-27 00:00 ET
DexCom published news for 2023 q2
SEC form 6
2023-06-23 18:04 ET
DexCom published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
DexCom published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
DexCom published news for 2023 q1
SEC form 10
2023-02-09 17:06 ET
DexCom published news for 2022 q4
SEC form 6
2023-02-09 16:05 ET
DexCom published news for 2022 q4
SEC form 8
2023-02-09 00:00 ET
DexCom reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
DexCom published news for
SEC form 6
2023-01-09 08:03 ET
DexCom published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
DexCom published news for 2022 q4
SEC form 10
2022-10-27 17:11 ET
DexCom published news for 2022 q3
SEC form 6
2022-10-27 16:05 ET
DexCom published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
DexCom reported for 2022 q3
SEC form 10
2022-10-27 00:00 ET
DexCom reported for 2022 q3
SEC form 6
2022-08-31 17:01 ET
DexCom published news for 2022 q2
SEC form 6
2022-08-05 16:52 ET
DexCom published news for 2022 q2
SEC form 10
2022-07-28 17:14 ET
DexCom published news for 2022 q2
SEC form 6
2022-07-28 16:23 ET
DexCom published news for 2022 q2
SEC form 6
2022-07-28 16:07 ET
DexCom published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
DexCom reported for 2022 q2
SEC form 10
2022-07-28 00:00 ET
DexCom reported for 2022 q2
SEC form 6
2022-07-08 16:30 ET
DexCom published news for 2022 q2
SEC form 6
2022-06-10 16:01 ET
DexCom published news for 2022 q1
SEC form 6
2022-05-20 09:01 ET
DexCom published news for 2022 q1
SEC form 10
2022-04-28 17:28 ET
DexCom published news for 2022 q1
SEC form 6
2022-04-28 16:08 ET
DexCom published news for 2022 q1
SEC form 10
2022-04-28 00:00 ET
DexCom reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
DexCom reported for 2022 q1
SEC form 6
2022-04-08 16:16 ET
DexCom published news for 2022 q1
SEC form 6
2022-03-25 16:25 ET
DexCom published news for 2021 q4
SEC form 6
2022-03-10 17:39 ET
DexCom published news for 2021 q4
SEC form 10
2022-02-14 16:31 ET
DexCom published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2022-02-10 16:08 ET
DexCom published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2022-01-26 17:42 ET
DexCom published news for 2021 q4
SEC form 6
2022-01-10 08:00 ET
DexCom published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2021-12-17 16:41 ET
DexCom published news for 2021 q3
SEC form 6
2021-11-22 17:03 ET
DexCom published news for 2021 q3
SEC form 10
2021-10-28 17:14 ET
DexCom published news for 2021 q3
SEC form 6
2021-10-28 16:06 ET
DexCom published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
DexCom published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
DexCom published news for 2021 q3
SEC form 6
2021-10-14 16:01 ET
DexCom published news for 2021 q3
SEC form 6
2021-09-14 16:29 ET
DexCom published news for 2021 q2
SEC form 6
2021-09-13 08:00 ET
DexCom published news for 2021 q2
SEC form 10
2021-07-29 17:19 ET
DexCom published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
DexCom published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
DexCom published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
DexCom published news for 2021 q2
SEC form 6
2021-06-30 18:58 ET
DexCom published news for 2021 q1
SEC form 6
2021-05-21 17:17 ET
DexCom published news for 2021 q1
SEC form 10
2021-04-29 17:17 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-29 16:03 ET
DexCom published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
DexCom published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-09 16:32 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 19:02 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 18:56 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 18:53 ET
DexCom published news for 2021 q1
SEC form 6
2021-03-26 16:08 ET
DexCom published news for 2020 q4
SEC form 6
2021-03-23 08:31 ET
DexCom published news for 2020 q4
SEC form 6
2021-03-17 14:22 ET
DexCom published news for 2020 q4
SEC form 10
2021-02-11 17:18 ET
DexCom published news for 2020 q4
SEC form 6
2021-02-11 16:04 ET
DexCom published news for 2020 q4
SEC form 6
2021-01-11 07:39 ET
DexCom published news for 2020 q4
SEC form 6
2020-12-10 16:15 ET
DexCom published news for 2020 q3
SEC form 6
2020-11-20 16:47 ET
DexCom published news for 2020 q3
SEC form 10
2020-10-27 17:11 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-27 16:08 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-26 17:24 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-13 16:37 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-13 10:50 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-05 18:12 ET
DexCom published news for 2020 q3